|
FDA Grants Accelerated Review For Pfizer Cancer Drug
Wall Street Journal The fusion of ALK with another gene is believed to be present in about 3% to 5% of people with non-small cell lung cancer, or 40000 patients diagnosed annually worldwide. Mace Rothenberg, senior vice president of clinical development & medical affairs … Pfizer Files NDA For Lung Cancer Drug Crizotinib With FDA, Japan – Update Pfizer cancer drug takes big step toward fateful FDA decision Pfizer Breaks Barriers with New Lung Cancer Drug |
View full post on lung cancer – Google News
